Role of interleukin-18 in the development and pathogenesis of AIDS

Alexandre Iannello, Suzanne Samaranil, Olfa Debbeche, Cécile Tremblay, Emil Toma, Mohamed Rachid Boulasse, Jean Pierre Routy, Ali Ahmad

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Interleukin-18 is a proinflammatory, proapoptotic, and proatherogenic cytokine belonging to the interleukin-1 family of cytokines. The cytokine exerts many unique immunologic and biological effects. It is produced as a biologically inactive and leaderless precursor protein, which must be cleaved into its mature form by caspase-1. The caspase-1 also exists in an inactive precursor in the cytosol and needs proteolytic auto-cleavage, which is catalyzed by the assembly of a multi-protein complex called inflammasome. Inside the circulation, interleukin-18 is bound to its naturally occurring antagonist called interleukin-18 binding protein. The antagonist is induced as a negative feedback to increased interleukin-18 production. It protects body cells and tissues from the potentially destructive and harmful proinflammatory effects of the cytokine. Several researchers have reported that the concentrations and biological activities of the cytokine are increased in the circulation of HIV-infected patients. Unlike interleukin-18, the concentrations of its antagonist, interleukin-18 binding protein, are decreased in these persons. The cytokine may play a major role in the development and pathogenesis of AIDS in HIV-infected persons. Insufficient/lack of interleukin-12 and related cytokines may compromise the ability of interleukin-18 to induce interferongamma production from natural killer and T-cells. By inducing production of T-helper 2-type cytokines like interleukin-4, -5, -9, and -13 from basophils and mast cells, interleukin-18 promotes the development and differentiation of CD4+ naive T-cells into T-helper 2-type effector cells, which blunt anti-HIV immunity. The effect may be more pronounced in HIV-infected persons with compromised production of interleukin-12. Interleukin-18 also directly enhances viral replication. Because of its proapoptotic effects, the cytokine decreases survivability and promotes the death of various immune and nonimmune cells. It has also been documented to play a role in the depletion and wasting of subcutaneous fat from the limbs and face. The wasting is a characteristic feature of HIV-associated lipodystrophy. The cytokine is also likely to be involved in the higher incidence of atherosclerotic plaques and systemic insulin resistance in these patients. Finally, increased production of the cytokine in the brain may lead to motor and cognitive dysfunctions, leading to the development of HIV-associated dementia. In conclusion, increased interleukin-18 concentrations in HIV-infected persons are likely to play an important role in the development and progression of the infection toward AIDS and associated clinical conditions. Therefore, its neutralization may represent an appropriate and useful immunotherapeutic strategy in these patients. It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein.

Original languageEnglish
Pages (from-to)115-125
Number of pages11
JournalAIDS Reviews
Volume11
Issue number3
Publication statusPublished - 2009

Fingerprint

Interleukin-18
Acquired Immunodeficiency Syndrome
Cytokines
HIV
Caspase 1
Interleukin-12
HIV-Associated Lipodystrophy Syndrome
AIDS Dementia Complex
Inflammasomes
Th2 Cells
Natural Killer T-Cells
Aptitude
Protein Precursors
Basophils
Subcutaneous Fat
Interleukin-5
Atherosclerotic Plaques
Interleukin-1
Mast Cells
Interleukin-4

Keywords

  • AIDS
  • Cytokines
  • HIV-1
  • HIV-associated dementia
  • IL-18
  • IL-18BP
  • Lipodystrophy

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Iannello, A., Samaranil, S., Debbeche, O., Tremblay, C., Toma, E., Boulasse, M. R., ... Ahmad, A. (2009). Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Reviews, 11(3), 115-125.

Role of interleukin-18 in the development and pathogenesis of AIDS. / Iannello, Alexandre; Samaranil, Suzanne; Debbeche, Olfa; Tremblay, Cécile; Toma, Emil; Boulasse, Mohamed Rachid; Routy, Jean Pierre; Ahmad, Ali.

In: AIDS Reviews, Vol. 11, No. 3, 2009, p. 115-125.

Research output: Contribution to journalReview article

Iannello, A, Samaranil, S, Debbeche, O, Tremblay, C, Toma, E, Boulasse, MR, Routy, JP & Ahmad, A 2009, 'Role of interleukin-18 in the development and pathogenesis of AIDS', AIDS Reviews, vol. 11, no. 3, pp. 115-125.
Iannello A, Samaranil S, Debbeche O, Tremblay C, Toma E, Boulasse MR et al. Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Reviews. 2009;11(3):115-125.
Iannello, Alexandre ; Samaranil, Suzanne ; Debbeche, Olfa ; Tremblay, Cécile ; Toma, Emil ; Boulasse, Mohamed Rachid ; Routy, Jean Pierre ; Ahmad, Ali. / Role of interleukin-18 in the development and pathogenesis of AIDS. In: AIDS Reviews. 2009 ; Vol. 11, No. 3. pp. 115-125.
@article{a723698fde774aa592258d67f5865689,
title = "Role of interleukin-18 in the development and pathogenesis of AIDS",
abstract = "Interleukin-18 is a proinflammatory, proapoptotic, and proatherogenic cytokine belonging to the interleukin-1 family of cytokines. The cytokine exerts many unique immunologic and biological effects. It is produced as a biologically inactive and leaderless precursor protein, which must be cleaved into its mature form by caspase-1. The caspase-1 also exists in an inactive precursor in the cytosol and needs proteolytic auto-cleavage, which is catalyzed by the assembly of a multi-protein complex called inflammasome. Inside the circulation, interleukin-18 is bound to its naturally occurring antagonist called interleukin-18 binding protein. The antagonist is induced as a negative feedback to increased interleukin-18 production. It protects body cells and tissues from the potentially destructive and harmful proinflammatory effects of the cytokine. Several researchers have reported that the concentrations and biological activities of the cytokine are increased in the circulation of HIV-infected patients. Unlike interleukin-18, the concentrations of its antagonist, interleukin-18 binding protein, are decreased in these persons. The cytokine may play a major role in the development and pathogenesis of AIDS in HIV-infected persons. Insufficient/lack of interleukin-12 and related cytokines may compromise the ability of interleukin-18 to induce interferongamma production from natural killer and T-cells. By inducing production of T-helper 2-type cytokines like interleukin-4, -5, -9, and -13 from basophils and mast cells, interleukin-18 promotes the development and differentiation of CD4+ naive T-cells into T-helper 2-type effector cells, which blunt anti-HIV immunity. The effect may be more pronounced in HIV-infected persons with compromised production of interleukin-12. Interleukin-18 also directly enhances viral replication. Because of its proapoptotic effects, the cytokine decreases survivability and promotes the death of various immune and nonimmune cells. It has also been documented to play a role in the depletion and wasting of subcutaneous fat from the limbs and face. The wasting is a characteristic feature of HIV-associated lipodystrophy. The cytokine is also likely to be involved in the higher incidence of atherosclerotic plaques and systemic insulin resistance in these patients. Finally, increased production of the cytokine in the brain may lead to motor and cognitive dysfunctions, leading to the development of HIV-associated dementia. In conclusion, increased interleukin-18 concentrations in HIV-infected persons are likely to play an important role in the development and progression of the infection toward AIDS and associated clinical conditions. Therefore, its neutralization may represent an appropriate and useful immunotherapeutic strategy in these patients. It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein.",
keywords = "AIDS, Cytokines, HIV-1, HIV-associated dementia, IL-18, IL-18BP, Lipodystrophy",
author = "Alexandre Iannello and Suzanne Samaranil and Olfa Debbeche and C{\'e}cile Tremblay and Emil Toma and Boulasse, {Mohamed Rachid} and Routy, {Jean Pierre} and Ali Ahmad",
year = "2009",
language = "English",
volume = "11",
pages = "115--125",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "3",

}

TY - JOUR

T1 - Role of interleukin-18 in the development and pathogenesis of AIDS

AU - Iannello, Alexandre

AU - Samaranil, Suzanne

AU - Debbeche, Olfa

AU - Tremblay, Cécile

AU - Toma, Emil

AU - Boulasse, Mohamed Rachid

AU - Routy, Jean Pierre

AU - Ahmad, Ali

PY - 2009

Y1 - 2009

N2 - Interleukin-18 is a proinflammatory, proapoptotic, and proatherogenic cytokine belonging to the interleukin-1 family of cytokines. The cytokine exerts many unique immunologic and biological effects. It is produced as a biologically inactive and leaderless precursor protein, which must be cleaved into its mature form by caspase-1. The caspase-1 also exists in an inactive precursor in the cytosol and needs proteolytic auto-cleavage, which is catalyzed by the assembly of a multi-protein complex called inflammasome. Inside the circulation, interleukin-18 is bound to its naturally occurring antagonist called interleukin-18 binding protein. The antagonist is induced as a negative feedback to increased interleukin-18 production. It protects body cells and tissues from the potentially destructive and harmful proinflammatory effects of the cytokine. Several researchers have reported that the concentrations and biological activities of the cytokine are increased in the circulation of HIV-infected patients. Unlike interleukin-18, the concentrations of its antagonist, interleukin-18 binding protein, are decreased in these persons. The cytokine may play a major role in the development and pathogenesis of AIDS in HIV-infected persons. Insufficient/lack of interleukin-12 and related cytokines may compromise the ability of interleukin-18 to induce interferongamma production from natural killer and T-cells. By inducing production of T-helper 2-type cytokines like interleukin-4, -5, -9, and -13 from basophils and mast cells, interleukin-18 promotes the development and differentiation of CD4+ naive T-cells into T-helper 2-type effector cells, which blunt anti-HIV immunity. The effect may be more pronounced in HIV-infected persons with compromised production of interleukin-12. Interleukin-18 also directly enhances viral replication. Because of its proapoptotic effects, the cytokine decreases survivability and promotes the death of various immune and nonimmune cells. It has also been documented to play a role in the depletion and wasting of subcutaneous fat from the limbs and face. The wasting is a characteristic feature of HIV-associated lipodystrophy. The cytokine is also likely to be involved in the higher incidence of atherosclerotic plaques and systemic insulin resistance in these patients. Finally, increased production of the cytokine in the brain may lead to motor and cognitive dysfunctions, leading to the development of HIV-associated dementia. In conclusion, increased interleukin-18 concentrations in HIV-infected persons are likely to play an important role in the development and progression of the infection toward AIDS and associated clinical conditions. Therefore, its neutralization may represent an appropriate and useful immunotherapeutic strategy in these patients. It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein.

AB - Interleukin-18 is a proinflammatory, proapoptotic, and proatherogenic cytokine belonging to the interleukin-1 family of cytokines. The cytokine exerts many unique immunologic and biological effects. It is produced as a biologically inactive and leaderless precursor protein, which must be cleaved into its mature form by caspase-1. The caspase-1 also exists in an inactive precursor in the cytosol and needs proteolytic auto-cleavage, which is catalyzed by the assembly of a multi-protein complex called inflammasome. Inside the circulation, interleukin-18 is bound to its naturally occurring antagonist called interleukin-18 binding protein. The antagonist is induced as a negative feedback to increased interleukin-18 production. It protects body cells and tissues from the potentially destructive and harmful proinflammatory effects of the cytokine. Several researchers have reported that the concentrations and biological activities of the cytokine are increased in the circulation of HIV-infected patients. Unlike interleukin-18, the concentrations of its antagonist, interleukin-18 binding protein, are decreased in these persons. The cytokine may play a major role in the development and pathogenesis of AIDS in HIV-infected persons. Insufficient/lack of interleukin-12 and related cytokines may compromise the ability of interleukin-18 to induce interferongamma production from natural killer and T-cells. By inducing production of T-helper 2-type cytokines like interleukin-4, -5, -9, and -13 from basophils and mast cells, interleukin-18 promotes the development and differentiation of CD4+ naive T-cells into T-helper 2-type effector cells, which blunt anti-HIV immunity. The effect may be more pronounced in HIV-infected persons with compromised production of interleukin-12. Interleukin-18 also directly enhances viral replication. Because of its proapoptotic effects, the cytokine decreases survivability and promotes the death of various immune and nonimmune cells. It has also been documented to play a role in the depletion and wasting of subcutaneous fat from the limbs and face. The wasting is a characteristic feature of HIV-associated lipodystrophy. The cytokine is also likely to be involved in the higher incidence of atherosclerotic plaques and systemic insulin resistance in these patients. Finally, increased production of the cytokine in the brain may lead to motor and cognitive dysfunctions, leading to the development of HIV-associated dementia. In conclusion, increased interleukin-18 concentrations in HIV-infected persons are likely to play an important role in the development and progression of the infection toward AIDS and associated clinical conditions. Therefore, its neutralization may represent an appropriate and useful immunotherapeutic strategy in these patients. It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein.

KW - AIDS

KW - Cytokines

KW - HIV-1

KW - HIV-associated dementia

KW - IL-18

KW - IL-18BP

KW - Lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=70049090013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049090013&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 115

EP - 125

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 3

ER -